Status:
COMPLETED
Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells
Lead Sponsor:
Universidad Nacional de Colombia
Collaborating Sponsors:
Fundación Salud de los Andes
Conditions:
Breast Cancer
Triple Negative Breast Cancer
Eligibility:
FEMALE
18-75 years
Phase:
PHASE1
Brief Summary
In this project, the investigators propose the first clinical study in Colombia of vaccination of patients with triple-negative breast cancer (TNBC) using synthetic peptides that contain mutations of ...
Detailed Description
EXECUTIVE SUMMARY. The achievements of personalized medicine in cancer research in developed countries make envision that various types of cancer in an advanced stage, will be in the medium term trea...
Eligibility Criteria
Inclusion
- Be a patient who is prescribed as a treatment for her cancer initiating neo-adjuvant chemotherapy with Doxorubicin / cyclophosphamide (A / C) administered prior to cycles with Taxanes and followed by surgery to remove the tumor.
- Be between 18 and 75 years old.
- That the patient agrees to participate in the Clinical Study prior to the start of chemotherapy.
- Have free venous access.
- Signature of informed consent.
Exclusion
- Heart disease.
- Diabetes
- Renal impairment
- Coagulation disorders
- Have been hospitalized in the last month
- Have another active tumor with the exception of skin tumors of the squamous-cell or basal-cell carcinoma.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04105582
Start Date
August 1 2019
End Date
February 1 2022
Last Update
June 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universidad Nacional de Colombia
Bogota, Cundinamarca, Colombia, 111321